摘要
目的:评价来氟米特联合甲氨蝶呤对类风湿关节炎的治疗效果和安全性。方法:选取2014年3月~2015年12月于我院风湿免疫科就诊的类风湿关节炎患者100例,随机均分为联合组和单纯组,联合组接受来氟米特合甲氨蝶呤治疗,单纯组只接受甲氨蝶呤单独治疗;治疗结束后比较两组临床症状改善情况,血沉、炎症相关因子改变指标等,并分析联合用药的安全性。结果:联合组临床症状和血清学指标改善情况均较单纯组明显(P〈0.05),药物副反应两组无明显差异(P〉0.05)。结论:联合运用来氟米特和甲氨蝶呤治疗类风湿关节炎疗效确切安全性高,临床应用时结合患者的疾病状况使用。
Objective:To evaluate the clinical efficacy and safety of leflunomide combined with methotrexate in rheumatoid arthritis.Methods:100 rheumatoid arthritis patients were collected,randomize into single group and combined group,both received methotrexate treat,while on this basis,combined group received methotrexate treat; the clinical symptoms improvement,ESR,inflammation-related factors were compared after treat,analyzed the security of combination therapy. Results:The clinical symptoms improvement and serology improved significantly in the combined group than single group(P 〈0.05); there was no difference in the adverse drug reactions(P 〈0.05). Conclusion:Leflunomide and methotrexate combination therapy in rheumatoid arthritis is effective,combine with the disease condition of the patient to medicate.
出处
《北方药学》
2016年第6期25-26,共2页
Journal of North Pharmacy